CAS: 64439-81-2; 4-Ethyl-4,9-Dihydroxy-1H-Pyrano[3',4':6,7]Indolizino[1,2-B]Quinoline-3,14(4H,12H)-Dione

上下游产品

methanol Camptothecin 1-oxide acetic acid 1,2,6,7-tetrahydr°Camptothecin -10-hydroxy-(20S)-camptothecin acetate salt9-(cyclohexylamino)methyl-10-hydroxy-(20S)-camptothecin acetate salt DB-67 9-amino-20(S)-camptothecin

5-甲氧基-2-氨基苯甲醛乙烯乙缩醛置于氢溴酸,氧气,对甲苯磺酸,二甲胺,Copper Dichloride体系中,用 水,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 24.5H,反应生成 10-羟基喜树碱
参考文献:植物抗肿瘤剂.18.喜树碱类似物的合成和生物活性.
标题:植物抗肿瘤剂.18.喜树碱类似物的合成和生物活性.
摘要:通过全合成获得喜树碱的四个类似物,即10-甲氧基(20),12-氮杂(29),苯并[j](36)和18-甲氧基(38).由完整的环e制备了两个水溶性类似物10-[(羧甲基)氧基]-(24)和10-[2'-(二乙氨基)-乙氧基]-20(S)-喜树碱(26).天然10羟基喜树碱(3).通常,P-388白血病系统的体外9Kb细胞毒性与活性之间存在非常好的相关性.尽管氮杂类似物29在p-388中的活性仅比天然喜树碱(1)高得多,但18-甲氧基类似物38的活性却与1相似.水溶性衍生物24是无活性的.胺盐酸盐26在高剂量水平下显示出优异的活性.这可能是由于其水解为3.dl-Camptothecin(17)的活性大约是1的一半,
DOI:10.1021/jm00179A016

专利信息

专利号:US-9765083-B2
优先权日:2013-12-03
标 题 :Method for the synthesis of irinotecan
发明人：ZABUDKIN ALEXANDER; MATVIENKO VIKTOR
权利人:SYNBIAS PHARMA AG
摘要:The present invention relates to a method for the synthesis of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (i.e. iriniotecan), comprising: (a) preparing 10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptotecin; and (b) selectively ethylating the compound of step (a) at the 7-position, thus resulting in the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin. The present invention is further directed to the use of 10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (i.e. 7-des-ethyl-irinotecan) as intermediate in a method for the synthesis of irinotecan as described.

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:US-5633260-A
优先权日:1994-04-19
标 题 :11,7 Substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
发明人：HAUSHEER FREDERICK H; HARIDAS KOCHAT
权利人:BIONUMERIK PHARMACEUTICALS INC
摘要:The novel compounds 11-hydroxy-7-ethyl camptothecin and 11-hydroxy-7-methoxy camptothecin (11,7-HECPT and 11,7-HMCPT) are active anticancer compounds which are poorly soluble in water. Because of their novelty, 11,7-HECPT and 11,7-HMCPT derivatives have not been directly administered by parenteral or oral routes to human subjects as an antitumor composition for the purpose of inhibiting the growth of cancer cells. The claimed compositions are useful as compared to the water soluble camptothecin derivatives, such as CPT-11, in clinical trials. The unpredictable interpatient variability in the metabolic production of an active metabolite from CPT-11 limits the utility of CPT-11. This invention overcomes these limitations by claiming novel pharmaceutically acceptable lactone stable formulations of 11,7-HECPT or 11,7-HMCPT, to directly administer to patients. The present invention also claims 11,7-HECPT and 11,7-HMCPT compositions, the synthesis of 11,7-HECPT or 11,7-HMCPT, the methods of formulation of 11,7-HECPT or 11,7 -HMCPT, and the methods of use of 11,7-HECPT or 11,7-HMCPT. Additionally, the claimed invention is directed to novel dosages, schedules, and routes of administration for both the 11,7-HECPT or 11,7-HMCPT formulations to humans with various forms of cancer. Other embodiments of this invention include isolation methods and methods of synthesis of certain camptothecin derivatives.

专利号:US-11413281-B2
优先权日:2016-07-11
标题:Ternary conjugate of antitumor drug, and synthesis and application
发明人：YU PENG; GUO NA; WANG DONG; TENG YUOU; Hao tiantian; LIU HUAN; ZHANG TIANLE; SHANG XIUZHUAN
权利人:UNIV TIANJIN SCIENCE & TECH
摘要:Disclosed is a targeted delivery system for a hydrophobic antitumor drug, referring to conjugates of E-selectin polypeptide ligand-polyethylene glycol-antitumor drug connected by different link bridges containing disulfide bonds. The synthesis of the conjugates, antitumor activity evaluation, the particle size and morphology characteristics of nanoparticles self-assembled by the conjugates in an aqueous solution, and the release of the antitumor drug in different conditions are comprised. The conjugates can actively target at vessels of a tumor site by the E-selectin peptide ligand, and can also self-assemble into nanoparticles in an aqueous solution, so as to be passively targeted at the tumor site by EPR effect. The results show that the conjugates have significant antitumor activity but are less toxic to normal cells, can inhibit the adhesion between tumor cells and vascular endothelial cells, have the potential of anti-tumor metastasis, and have a broad prospect in development and application of antitumor drugs.

专利号:US-7151179-B2
优先权日:2003-05-12
标题 :Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
发明人：LIN CHIEN-HSING; CHEN YUNG-FA; CHEN KAU-MING
权利人:SCINOPHARM TAIWAN LTD
摘要:The key intermediate in any synthesis of Irinotecan is 7-ethyl-10-hydroxy-20(S)-camptothecin. A process for the efficient synthesis of this intermediate is demonstrated proceeding through readily available 20(S)-camptothecin. Various other tecan compounds may be made by use of corresponding 7-alkyl-10-hydroxy-20(S)-camptothecin intermediates.

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.